OBJECTIVE: Female breast cancer patients carrying a BRCA1/2-mutation have an increased risk of second primary breast and ovarian tumors. Little is known about the psychological impact and treatment consequences of rapid genetic counseling and testing offered between breast cancer diagnosis and surgery. METHODS: Female breast cancer patients, who had received rapid genetic counseling (and optional testing) (RGC(T)) at The Netherlands Cancer Institute between 2004 and 2008, received a questionnaire in 2009. RESULTS: BRCA-mutations were found in 10 of the 26 participants. Six mutation-carriers (60%) had an immediate bilateral mastectomy, compared with 25% of those without a mutation. Five patients (19%) reported having frequent worries about cancer recurrence; none indicated that such worries impaired daily functioning. Six patients had clinically relevant levels of breast cancer-specific distress at the time of assessment. CONCLUSION: These results suggest that RGC(T) in high-risk breast cancer patients may influence surgical treatment, without causing long-term psychosocial distress in the majority. PRACTICE IMPLICATIONS: These results are important, since rapid genetic counseling and testing are expected to be offered to newly diagnosed breast cancer patients with increasing frequency in order to inform these women and their surgeons about the possible familial/hereditary nature of their disease before deciding on treatment.
OBJECTIVE: Female breast cancerpatients carrying a BRCA1/2-mutation have an increased risk of second primary breast and ovarian tumors. Little is known about the psychological impact and treatment consequences of rapid genetic counseling and testing offered between breast cancer diagnosis and surgery. METHODS: Female breast cancerpatients, who had received rapid genetic counseling (and optional testing) (RGC(T)) at The Netherlands Cancer Institute between 2004 and 2008, received a questionnaire in 2009. RESULTS:BRCA-mutations were found in 10 of the 26 participants. Six mutation-carriers (60%) had an immediate bilateral mastectomy, compared with 25% of those without a mutation. Five patients (19%) reported having frequent worries about cancer recurrence; none indicated that such worries impaired daily functioning. Six patients had clinically relevant levels of breast cancer-specific distress at the time of assessment. CONCLUSION: These results suggest that RGC(T) in high-risk breast cancerpatients may influence surgical treatment, without causing long-term psychosocial distress in the majority. PRACTICE IMPLICATIONS: These results are important, since rapid genetic counseling and testing are expected to be offered to newly diagnosed breast cancerpatients with increasing frequency in order to inform these women and their surgeons about the possible familial/hereditary nature of their disease before deciding on treatment.
Authors: Shoshana M Rosenberg; Kathryn J Ruddy; Rulla M Tamimi; Shari Gelber; Lidia Schapira; Steven Come; Virginia F Borges; Bryce Larsen; Judy E Garber; Ann H Partridge Journal: JAMA Oncol Date: 2016-06-01 Impact factor: 31.777
Authors: Reshma Jagsi; Kent A Griffith; Allison W Kurian; Monica Morrow; Ann S Hamilton; John J Graff; Steven J Katz; Sarah T Hawley Journal: J Clin Oncol Date: 2015-04-06 Impact factor: 44.544
Authors: Akiva P Novetsky; Kylie Smith; Sheri A Babb; Donna B Jeffe; Andrea R Hagemann; Premal H Thaker; Matthew A Powell; David G Mutch; L Stewart Massad; Israel Zighelboim Journal: Int J Gynecol Cancer Date: 2013-07 Impact factor: 3.437
Authors: Nicky Dekker; Eleonora B L van Dorst; Rob B van der Luijt; Marielle E van Gijn; Marc van Tuil; Johan A Offerhaus; Margreet G E M Ausems Journal: J Genet Couns Date: 2012-11-30 Impact factor: 2.537
Authors: Marijke R Wevers; Margreet G E M Ausems; Senno Verhoef; Eveline M A Bleiker; Daniela E E Hahn; Titia Brouwer; Frans B L Hogervorst; Rob B van der Luijt; Thijs van Dalen; Evert B Theunissen; Bart van Ooijen; Marnix A de Roos; Paul J Borgstein; Bart C Vrouenraets; Eline Vriens; Wim H Bouma; Herman Rijna; Johannes P Vente; Jacobien M Kieffer; Heiddis B Valdimarsdottir; Emiel J Th Rutgers; Arjen J Witkamp; Neil K Aaronson Journal: Genet Med Date: 2015-04-23 Impact factor: 8.822
Authors: Sarah Wright; Mary Porteous; Diane Stirling; Julia Lawton; Oliver Young; Charlie Gourley; Nina Hallowell Journal: J Genet Couns Date: 2018-05-11 Impact factor: 2.537